The U.S. Food and Drug Administration (FDA) has approved Qbrexza (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis in pediatric patients aged 9 years and older. This approval expands the use of Qbrexza, a topical anticholinergic, to a younger population suffering from excessive underarm sweating. This marks a significant advancement as it provides the first topical anticholinergic treatment option specifically indicated for children with this condition.
Clinical Trial Data
The approval was supported by data from a Phase 3 clinical trial evaluating the safety and efficacy of Qbrexza in pediatric patients. The study demonstrated a statistically significant reduction in sweat production in the treatment group compared to the placebo group. Key endpoints included the Hyperhidrosis Disease Severity Scale-Children (HDSS-C) and gravimetric assessment of sweat production. Specific data points, including p-values and confidence intervals, were submitted to the FDA as part of the approval process.
Mechanism of Action
Qbrexza works by blocking the action of acetylcholine, a chemical messenger that stimulates sweat glands. By inhibiting acetylcholine's binding to its receptors on sweat glands, Qbrexza reduces sweat production in the treated area. The topical formulation allows for targeted delivery of the medication, minimizing systemic exposure.
Current Treatment Landscape and Unmet Needs
Prior to this approval, treatment options for pediatric hyperhidrosis were limited and often involved off-label use of adult formulations or more invasive procedures. The availability of a safe and effective topical treatment specifically formulated for children addresses a significant unmet medical need. Hyperhidrosis can have a profound impact on a child's self-esteem, social interactions, and overall quality of life. Qbrexza offers a convenient, once-daily application, potentially improving adherence and outcomes in this patient population.
Dosing and Administration
Qbrexza is applied topically to the underarms once daily. Healthcare providers should instruct patients on proper application techniques and potential side effects, which may include dry mouth, blurred vision, and urinary retention. The safety and efficacy of Qbrexza have not been established in children under the age of 9 years.
